The SARS-CoV-2 pandemic is a worldwide public health emergency. Despite the beginning of a vaccination campaign, the search for new drugs to appropriately treat COVID-19 patients remains a priority. Drug repur-posing represents a faster and cheaper method than de novo drug discovery. In this study, we examined three different network-based approaches to identify potentially repurposable drugs to treat COVID-19. We analyzed transcriptomic data from whole blood cells of patients with COVID-19 and 21 other related conditions, as compared with those of healthy subjects. In addition to conventionally used drugs (e.g., anticoagulants, anti-histaminics, anti-TNFα antibodies, corticosteroids), unconventional candidate compounds, such as SCN5A in-hibitors and drugs active in the central nervous system, were identified. Clinical judgment and validation through clinical trials are always mandatory before use of the identified drugs in a clinical setting.
2021, BIOMÉDECINE & PHARMACOTHÉRAPIE, Pages 1-10 (volume: 142)
In silico drug repurposing in COVID-19. A network-based analysis (01a Articolo in rivista)
Sibilio Pasquale, Bini Simone, Fiscon Giulia, Sponziello Marialuisa, Conte Federica, Pecce Valeria, Durante Cosimo, Paci Paola, Falcone Rosa, Norata Giuseppe Danilo, Farina Lorenzo, Verrienti Antonella
Gruppo di ricerca: Bioengineering and Bioinformatics